Aurlide
Private Company
Funding information not available
Overview
Aurlide is a Turku-based, service-oriented biotech leveraging a proprietary virtual high-throughput screening (vHTS) platform to accelerate early-stage small molecule discovery for clients. The company boasts a strong track record, having contributed to five clinical candidates, out-licensed two projects, and secured 14 patents. Its core value proposition is significantly increasing hit rates and streamlining hit-to-lead optimization, thereby saving clients time and cost while reducing pre-clinical failure risks.
Technology Platform
Proprietary virtual High-Throughput Screening (vHTS) platform for small molecule hit identification and optimization. Capable of hit space expansion, core hopping, and simultaneous optimization for binding to human and animal species proteins.
Opportunities
Risk Factors
Competitive Landscape
Aurlide competes in the computational drug discovery segment against large public software companies (e.g., Schrödinger), pure-play AI/biotech platforms (e.g., Exscientia, Recursion), and numerous other boutique CROs offering computational chemistry services. Its differentiation is claimed through a high hit rate for first-in-class molecules and a specific focus on hit expansion and dual-species optimization.